

CONTENTS

Feature Articles : Surrogate Biomarkers for Clinical Trials of Cardiovascular Drugs

Editorial	Shinichiro UEDA	293
1. Surrogate Biomarkers : Clinical Significance and Limitation	Shinichiro UEDA	295
2. Blood Pressure, Glucose, and Cholesterol as the Surrogate Markers for the Cardiovascular Events : Review of the Association between these Parameters and the Outcome of Intervention Studies	Hidekatsu YANAI, et al.	299
3. Consensus Statement on the Measurement of Flow-Mediated vasoDilation as a Surrogate Marker of Cardiovascular Diseases	Hidehiro MATSUOKA, et al.	305
4. Application of Surrogate Marker in Clinical Trials ; Diabetes Mellitus and Metabolic Syndrome	Michio SHIMABUKURO	311
5. Clinical Trials Using Surrogate Markers to Predict Outcome of Coronary Heart Disease	Shigemasa HASHIMOTO, et al.	317

Original

A Randomized Controlled Study on the Effects of Gargling with Tea Catechin Extracts on the Prevention of Influenza Infection in Healthy Adults	Hiroshi YAMADA, et al.	323
Pharmacokinetic and Pharmacodynamic Properties of Intravenous Darbepoetin Alfa (KRN321) in Japanese Hemodialysis Patients	Toshihiko UEMATSU, et al.	331

Forum

The Current Situation and Problems in Clinical Trials with Electronic Medical Record System	Kaoru ISHIYAMA, et al.	341
Questionnaire to General Citizens on Human Tissue Bank for Research Use	Takako MAEKAWA, et al.	349
Proposals for Improving the Japanese Clinical Trial Environment to Increase International Competitiveness : Based on the Results of the EFPIA Survey on the Japanese Clinical Trial Environment	Akimitsu SANNO, et al.	355

Report

Study of Genetics-Based Treatment Strategy of Gastrointestinal Disorders	Takahisa FURUTA	363
--	-----------------	-----

Drug Information

145E

The Regulations of JSCPT

147E

List of Members of JSCPT Board

153E

List of Members of JSCPT

157E

Information for Authors

191E

Announcements

193E